Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + TACE in localized unresectable HCC
NCT01379521Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2011
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Everolimus + TACE with Placebo + TACE (2 arms). Primary endpoint: Time to Progression at 24 months. Started Jun 2011; status: terminated.
02
Drugs
everolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01379521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01379521.